Latest Kaiser Health News Stories
As drugmakers hike prices, interest to rein them in grows on Capitol Hill. Next week marks the anniversary of Roe v. Wade, the Supreme Court’s abortion decision, and both the House, whose leaders back abortion rights, and the Senate, controlled by abortion foes, are holding statement votes. And the government shutdown is still affecting health programs. Joanne Kenen of Politico, Margot Sanger-Katz of The New York Times and Alice Ollstein of Politico join KHN’s Julie Rovner to discuss these issues.
While headlines continue to focus on the nation’s opioid crisis, a growing toll of overdoses and deaths related to methamphetamine use suggests this drug is making an under-the-radar comeback.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
In a recent study of patients treated by emergency medical responders in Oregon, black patients were 40 percent less likely to get pain medicine than their white peers. Why?
Loretta Boesing is on a mission to make sure prescription drugs delivered by mail are safe and effective. The life of her son — and others who order medicine by mail — could depend on it, she says.
Critics say patients are often misled by ads that advocate high-priced drugs or genetic tests.
A reporter with a serious peanut allergy explains what it is like to process news reports that tout new pharmaceutical products that might minimize the danger of accidental exposure.
The Food and Drug Administration is supposed to inspect all factories, foreign and domestic, that produce drugs for the U.S. market. But a KHN review of thousands of FDA documents — inspection records, recalls, warning letters and lawsuits — reveals how drugs that are poorly manufactured or contaminated can reach consumers.
The program that provides health care for about half of the U.S. territory’s population cannot afford to cover the drugs.
From Medicare dental coverage to drug prices to fetal tissue research, the panelists answer listeners’ questions. Joanne Kenen of Politico, Stephanie Armour of The Wall Street Journal and Paige Winfield Cunningham of The Washington Post join KHN’s Julie Rovner.
Utah’s Orrin Hatch is leaving the Senate, after 42 years. The Republican led bipartisan efforts to provide health care to more kids and AIDS patients. He also thrived on donations from the drug industry.
The fallout continues from that Texas court decision that ruled Congress’ 2017 elimination of the tax penalty for failing to have insurance rendered the entire Affordable Care Act unconstitutional. Meanwhile, enrollment for 2019 at healthcare.gov was down, but far less than many predicted. KHN’s Julie Rovner, along with panelists Joanne Kenen of Politico, Anna Edney of Bloomberg News and Kimberly Leonard of the Washington Examiner, discuss this, plus the best, most overhyped and nerdiest stories of 2018. Also, Rovner interviews GOP strategist and pollster Frank Luntz.
Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from “biosimilars.” It’s a very different story in Europe.
The leaders of California’s legislative health committees who wield power over state health policy have been showered with money from the health care sector, with drug companies, health plans, hospitals and doctors providing nearly 40 percent of their 2017-18 campaign funds.
The U.S. surgeon general has called on “bystanders” to be equipped with the opioid reversal drug to save lives. But when a nurse answered that call, her application for life insurance was denied. Why?
It’s a little-known secret that patients can get thousands of dollars directly from a drugmaker.
The price of insulin keeps going up. For people with Type 1 diabetes, high prices can be a life-or-death issue. Now a grass-roots movement is pushing for change.